Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
yAnd80MeA5ZJQzru
Listen
